Apyx Medical Corporation (NASDAQ:APYX) is set to announce second quarter earning results on Monday 10th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, APYX to report 2Q20 loss of $ 0.21 per share.
For the full year, analysts anticipate top line of $ 17.14 million, while looking forward to loss of $ 0.66 per share bottom line.
Previous Quarter Performance
Apyx Medical Corporation revealed loss for the first quarter of $ 0.20 per share, from the revenue of $ 5.00 million. The quarterly revenues shrunk 11.82 percent compared with the same quarter last year. Street analysts expected Apyx Medical Corporation to report loss of $ 0.25 per share on revenue of $ 5.20 million for the first quarter. The bottom line results beat street analysts by $ 0.05 or 20.00 percent, at the same time, top line results fell short of analysts by $ 0.2 million or 3.85 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Apyx Medical Corporation
Stock Performance
According to the previous trading day, closing price of APYX was $ 5.00, representing a 77.94 % increase from the 52 week low of $ 2.81 and a 41.79 % decrease over the 52 week high of $ 8.59.
The company has a market capital of $ 170.92 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”APYX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Apyx Medical Corporation will be hosting a conference call at 8:00 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website apyxmedical.com
Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.
